ArticlePloS one2014
Long leukocyte telomere length at diagnosis is a risk factor for dementia progression in idiopathic parkinsonism.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Short telomere length is associated with impaired cognitive performance in European ancestry cohorts.Translational psychiatry · 2017Pooled it
- Telomere length in Parkinson's disease: A meta-analysis.Experimental gerontology · 2016Pooled it
- Preliminary insights into whole-blood mitochondrial DNA copy number and telomere length in Parkinson's disease and multiple system atrophy.Journal of neurology · 2026Article
- Interplay Between 3D Chromatin Architecture and Gene Regulation at theInternational journal of molecular sciences · 2025Article
- The relationship between telomere length and aging-related diseases.Clinical and experimental medicine · 2025Review
- Risk factors and predictors for Lewy body dementia: a systematic review.NPJ dementia · 2025Article
- Article
- Mitochondrial biogenesis, telomere length and cellular senescence in Parkinson's disease and Lewy body dementia.Scientific reports · 2022Article
- Leukocyte Telomere Length Variability as a Potential Biomarker in Patients with PolyQ Diseases.Antioxidants (Basel, Switzerland) · 2022Article
- Is Telomere Length Shortening a Risk Factor for Neurodegenerative Disorders?Dementia and neurocognitive disorders · 2022Review
- Genetically predicted telomere length and its relationship with neurodegenerative diseases and life expectancy.Computational and structural biotechnology journal · 2022Article
- Age-Related Adaptive Immune Changes in Parkinson's Disease.Journal of Parkinson's disease · 2022Review
- T lymphocyte senescence is attenuated in Parkinson's disease.Journal of neuroinflammation · 2021Article
- Assessment of the Telomere Length and Its Effect on the Symptomatology of Parkinson's Disease.Antioxidants (Basel, Switzerland) · 2021Article
- Leukocyte Telomere Length Is Unrelated to Cognitive Performance Among Non-Demented and Demented Persons: An Examination of Long Life Family Study Participants.Journal of the International Neuropsychological Society : JINS · 2020Article
- Telomere Attrition in Neurodegenerative Disorders.Frontiers in cellular neuroscience · 2020Article
- Cellular Senescence in Neurodegenerative Diseases.Frontiers in cellular neuroscience · 2020Review
- Senescence and Inflammatory Markers for Predicting Clinical Progression in Parkinson's Disease: The ICICLE-PD Study.Journal of Parkinson's disease · 2020Article
- An integrated transcriptome analysis in T-cell acute lymphoblastic leukemia links DNA methylation subgroups to dysregulated TAL1 and ANTP homeobox gene expression.Cancer medicine · 2019Article
- Ageing, Cellular Senescence and Neurodegenerative Disease.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Telomere length (TL) is regarded as a marker of cellular aging due to the gradual shortening by each cell division, but is influenced by a number of factors including oxidative stress and inflammation. Parkinson's disease and atypical forms of parkinsonism occur mainly in the elderly, with oxidative stress and inflammation in afflicted cells. In this study the relationship between blood TL and prognosis of 168 patients with idiopathic parkinsonism (136 Parkinson's disease [PD], 17 Progressive Supranuclear Palsy [PSP], and 15 Multiple System Atrophy [MSA]) and 30 controls was investigated. TL and motor and cognitive performance were assessed at baseline (diagnosis) and repeatedly up to three to five years follow up. No difference in TL between controls and patients was shown at baseline, nor any significant difference in TL stability or attrition during follow up. Interestingly, a significant relationship between TL at diagnosis and cognitive phenotype at follow up in PD and PSP patients was found, with longer mean TL at diagnosis in patients that developed dementia within three years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.